KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash from Financing Activities (2018 - 2025)

Vir Biotechnology's Cash from Financing Activities history spans 8 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 17.74% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $3.8 million, down 13.74%, while the annual FY2025 figure was $3.8 million, 13.74% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $1.0 million at Vir Biotechnology, up from $102000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $87.5 million in Q1 2021 and bottomed at $31000.0 in Q3 2024.
  • The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $7.5 million.
  • The largest YoY upside for Cash from Financing Activities was 102844.71% in 2021 against a maximum downside of 98.88% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at $5.7 million in 2021, then plummeted by 64.53% to $2.0 million in 2022, then dropped by 16.46% to $1.7 million in 2023, then decreased by 24.82% to $1.3 million in 2024, then fell by 17.74% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Cash from Financing Activities are $1.0 million (Q4 2025), $102000.0 (Q3 2025), and $2.0 million (Q2 2025).